{"id":"filgrastim-injectable-product","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bone pain"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL1201567","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells, particularly neutrophils, by binding to and activating the G-CSF receptor.","oneSentence":"Stimulates the production of white blood cells by binding to and activating the G-CSF receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:10.422Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neutropenia"},{"name":"Febrile neutropenia"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT07059611","phase":"PHASE2","title":"Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-01","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":34},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":"RUNX1 Familial Platelet Disorder","enrollment":4},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT06465160","phase":"PHASE1","title":"A Study to Evaluate the MNV-201 in Patients With Low Risk MDS","status":"RECRUITING","sponsor":"Minovia Therapeutics Ltd.","startDate":"2024-05-27","conditions":"Myelodysplastic Syndromes","enrollment":15},{"nctId":"NCT06547112","phase":"PHASE1","title":"A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2024-10-31","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT07064018","phase":"PHASE1, PHASE2","title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-04-30","conditions":"Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer","enrollment":67},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT02582697","phase":"PHASE3","title":"Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","status":"RECRUITING","sponsor":"University of Sydney","startDate":"2014-02","conditions":"Germ Cell Tumor","enrollment":500},{"nctId":"NCT03944915","phase":"PHASE2","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-08-26","conditions":"Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck","enrollment":35},{"nctId":"NCT04958772","phase":"PHASE1","title":"Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Megalabs","startDate":"2024-11-01","conditions":"Healthy","enrollment":100},{"nctId":"NCT04651439","phase":"PHASE2, PHASE3","title":"Severe Bullous Drug Eruption and Filgrastim","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-05-13","conditions":"Rare Diseases, Toxic Epidermal Necrolyses","enrollment":42},{"nctId":"NCT00837265","phase":"PHASE2, PHASE3","title":"Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2008-08-21","conditions":"Chemotherapy-induced Neutropenia","enrollment":334},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT06188676","phase":"PHASE3","title":"Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2022-04-01","conditions":"Primary Mediastinal Lymphoma","enrollment":100},{"nctId":"NCT05118113","phase":"NA","title":"Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors","status":"UNKNOWN","sponsor":"Smart Immune SAS","startDate":"2022-04-26","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT02642965","phase":"PHASE1, PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2016-05-02","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":38},{"nctId":"NCT00046930","phase":"PHASE3","title":"Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2002-09-17","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":449},{"nctId":"NCT05876832","phase":"PHASE3","title":"A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)","status":"NOT_YET_RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2023-06-15","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":312},{"nctId":"NCT05817955","phase":"PHASE2","title":"Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-11-01","conditions":"MDS/MPN","enrollment":50},{"nctId":"NCT05790096","phase":"PHASE3","title":"Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy","status":"UNKNOWN","sponsor":"Blau Farmaceutica S.A.","startDate":"2023-05","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT01126190","phase":"PHASE3","title":"Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-06-30","conditions":"Chemotherapy-induced Neutropenia","enrollment":381},{"nctId":"NCT03029000","phase":"PHASE3","title":"Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-08-02","conditions":"Healthy Participants","enrollment":1},{"nctId":"NCT03612466","phase":"PHASE1","title":"A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy","status":"WITHDRAWN","sponsor":"Albert Einstein College of Medicine","startDate":"2022-08","conditions":"Osteosarcoma, Bone Metastases","enrollment":""},{"nctId":"NCT02479646","phase":"PHASE1","title":"Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-09","conditions":"Healthy Volunteers","enrollment":218},{"nctId":"NCT03686228","phase":"NA","title":"Treatment of No-option CLI by G-CSF-mobilized PB-MNC","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2018-10-01","conditions":"PAD, Critical Limb Ischemia, Atherosclerotic Ischemic Disease","enrollment":40},{"nctId":"NCT00001048","phase":"PHASE2","title":"Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Leukoencephalopathy, Progressive Multifocal","enrollment":90},{"nctId":"NCT04622956","phase":"PHASE1, PHASE2","title":"GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-07","conditions":"Graft Vs Host Disease, Hematopoietic Neoplasm","enrollment":47},{"nctId":"NCT03511378","phase":"PHASE4","title":"Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2018-03-06","conditions":"Breast Cancer","enrollment":138},{"nctId":"NCT03486080","phase":"PHASE2","title":"Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction","status":"COMPLETED","sponsor":"Recardio, Inc.","startDate":"2018-12-07","conditions":"Acute Myocardial Infarction, Acute Myocardial Ischemia, STEMI - ST Elevation Myocardial Infarction","enrollment":49},{"nctId":"NCT04773327","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies","status":"UNKNOWN","sponsor":"Xiaohua Wu MD","startDate":"2021-05","conditions":"Gynecologic Malignant Tumor","enrollment":150},{"nctId":"NCT01753453","phase":"PHASE2","title":"An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Multiple Myeloma","enrollment":23},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300},{"nctId":"NCT00821249","phase":"PHASE1, PHASE2","title":"A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":55},{"nctId":"NCT02092922","phase":"PHASE2","title":"A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-05","conditions":"Advanced Multiple Myeloma","enrollment":154},{"nctId":"NCT01896856","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-10-23","conditions":"Previously Treated Metastatic Colorectal Cancer","enrollment":118},{"nctId":"NCT01248923","phase":"PHASE1","title":"A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2010-12","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":55},{"nctId":"NCT00462358","phase":"PHASE1","title":"A Study of ARRY-520 in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Advanced Solid Tumors","enrollment":41},{"nctId":"NCT01989325","phase":"PHASE2","title":"A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-11","conditions":"Advanced Multiple Myeloma","enrollment":77},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT02921061","phase":"PHASE1, PHASE2","title":"Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-11-17","conditions":"Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT04239001","phase":"NA","title":"Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-02","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT00140140","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2005-08","conditions":"Stage IV (Metastatic) Breast Cancer","enrollment":16},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT03251768","phase":"PHASE2","title":"Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-10-19","conditions":"Chemotherapy-induced Neutropenia","enrollment":80},{"nctId":"NCT03870412","phase":"NA","title":"Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-22","conditions":"Elderly Lymphoma Patients","enrollment":485},{"nctId":"NCT00416598","phase":"PHASE2","title":"Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11-15","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","enrollment":546},{"nctId":"NCT03559387","phase":"PHASE2","title":"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","status":"TERMINATED","sponsor":"Prolong Pharmaceuticals","startDate":"2017-08-03","conditions":"Chemotherapy-induced Neutropenia","enrollment":9},{"nctId":"NCT03776604","phase":"NA","title":"PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2018-12-05","conditions":"Small Cell Lung Cancer, PEG-rhG-CSF","enrollment":61},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00228813","phase":"NA","title":"G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome","status":"TERMINATED","sponsor":"Emory University","startDate":"2004-04","conditions":"Hematologic Malignancies","enrollment":8},{"nctId":"NCT02465801","phase":"PHASE2","title":"Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2014-12-16","conditions":"Chemotherapy-induced Neutropenia","enrollment":216},{"nctId":"NCT01467115","phase":"PHASE2","title":"Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2010-03","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT00238173","phase":"PHASE1","title":"Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-12","conditions":"Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ","enrollment":2},{"nctId":"NCT00943943","phase":"PHASE1","title":"Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-10-29","conditions":"Acute Myelogenous Leukemia, Leukemia","enrollment":33},{"nctId":"NCT02923791","phase":"PHASE1","title":"A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10","conditions":"Healthy Volunteers","enrollment":256},{"nctId":"NCT02766634","phase":"PHASE1","title":"A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-03","conditions":"Neutropenia (Low White Blood Cell Count)","enrollment":60},{"nctId":"NCT02766647","phase":"PHASE1","title":"A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12","conditions":"Neutropenia (Low White Blood Cell Count)","enrollment":24},{"nctId":"NCT01859637","phase":"PHASE4","title":"Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia","status":"TERMINATED","sponsor":"Sandoz","startDate":"2011-07","conditions":"Severe Chronic Neutropenia","enrollment":6},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT01918241","phase":"PHASE2","title":"Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","startDate":"2013-07","conditions":"Neutropenia","enrollment":200},{"nctId":"NCT01016795","phase":"PHASE2","title":"Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma","status":"TERMINATED","sponsor":"Aalborg University Hospital","startDate":"1999-01","conditions":"Malignant Lymphoma","enrollment":32},{"nctId":"NCT01933971","phase":"PHASE1","title":"Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®","status":"COMPLETED","sponsor":"Bio-ker S.r.l.","startDate":"2007-06","conditions":"Healthy Male Subjects","enrollment":102},{"nctId":"NCT01617577","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Filgrastim in Alzheimer's Disease","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2009-06","conditions":"Alzheimer's Disease","enrollment":8},{"nctId":"NCT00054665","phase":"PHASE2","title":"PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-02","conditions":"B-Cell Lymphoma","enrollment":50},{"nctId":"NCT00770172","phase":"PHASE3","title":"G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy","status":"COMPLETED","sponsor":"Centre Francois Baclesse","startDate":"2007-10","conditions":"Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["filgrastim"],"phase":"phase_2","status":"active","brandName":"Filgrastim Injectable Product","genericName":"Filgrastim Injectable Product","companyName":"Recardio, Inc.","companyId":"recardio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stimulates the production of white blood cells by binding to and activating the G-CSF receptor. Used for Neutropenia, Febrile neutropenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}